CLINICAL DRUG INVESTIGATION

CLINICAL DRUG INVESTIGATION

CLIN DRUG INVEST
影响因子:2.7
是否综述期刊:
是否预警:不在预警名单内
是否OA:
出版国家/地区:NEW ZEALAND
出版社:Springer International Publishing
发刊时间:1989
发刊频率:Monthly
收录数据库:SCIE/Scopus收录
ISSN:1173-2563

期刊介绍

Clinical Drug Investigation provides rapid publication of original research covering all phases of clinical drug development and therapeutic use of drugs. The Journal includes:-Clinical trials, outcomes research, clinical pharmacoeconomic studies and pharmacoepidemiology studies with a strong link to optimum prescribing practice for a drug or group of drugs.-Clinical pharmacodynamic and clinical pharmacokinetic studies with a strong link to clinical practice.-Pharmacodynamic and pharmacokinetic studies in healthy volunteers in which significant implications for clinical prescribing are discussed.-Studies focusing on the application of drug delivery technology in healthcare.-Short communications and case study reports that meet the above criteria will also be considered.Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Clinical Drug Investigation may be accompanied by plain language summaries to assist readers who have some knowledge, but non in-depth expertise in, the area to understand important medical advances.
临床药物研究提供涵盖临床药物开发和药物治疗使用所有阶段的原创研究的快速出版。该杂志包括:-临床试验,结果研究,临床药物经济学研究和药物流行病学研究与一种药物或一组药物的最佳处方实践的强有力的联系。临床药效学和临床药代动力学研究与临床实践密切相关。-在健康志愿者中进行的药效学和药代动力学研究,其中讨论了临床处方的重要意义。重点研究药物输送技术在医疗保健中的应用。-符合上述标准的简短交流和案例研究报告也将被考虑。其他数字功能(包括动画摘要、视频摘要、幻灯片、音频幻灯片、教学视频、信息图表、播客和动画)可以与文章一起发表;目的是提高刊物的知名度、读者群和教育价值。此外,在《临床药物研究》上发表的文章可能附有简明扼要的总结,以帮助在该领域有一定知识但没有深入专业知识的读者了解重要的医学进展。
年发文量 67
国人发稿量 15.4
国人发文占比 0.23%
自引率 -
平均录取率0
平均审稿周期 较慢,6-12周
版面费 US$3500
偏重研究方向 医学-药学
期刊官网 https://www.springer.com/40261
投稿链接 https://www.editorialmanager.com/cdia/

期刊高被引文献

来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
Emerging Trends in Metformin Prescribing in the United States from 2000 to 2015
来源期刊:Clinical Drug InvestigationDOI:10.1007/s40261-019-00799-0
Effect of Selective Serotonin Reuptake Inhibitors on Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Retrospective Cohort Study
来源期刊:Clinical Drug InvestigationDOI:10.1007/s40261-019-00776-7
RETRACTED ARTICLE: Fetal Safety of Dydrogesterone Exposure in the First Trimester of Pregnancy
来源期刊:Clinical Drug InvestigationDOI:10.1007/s40261-019-00862-w
Opioid Use and Pain Control in the Elderly After Elective or Urgent Orthopaedic Surgery: A Retrospective Cohort Study
来源期刊:Clinical Drug InvestigationDOI:10.1007/s40261-018-00744-7
Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study
来源期刊:Clinical Drug InvestigationDOI:10.1007/s40261-019-00855-9
Drug–Drug Interactions in Children and Adolescents Receiving Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Virus Infection
来源期刊:Clinical Drug InvestigationDOI:10.1007/s40261-019-00805-5
The Prediction Model of Warfarin Individual Maintenance Dose for Patients Undergoing Heart Valve Replacement, Based on the Back Propagation Neural Network
来源期刊:Clinical Drug InvestigationDOI:10.1007/s40261-019-00850-0
Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis: A Profile of Its Use
来源期刊:Clinical Drug InvestigationDOI:10.1007/s40261-019-00853-x
Comparison of Safety Profiles of New Oral Anticoagulants with Warfarin Using the Japanese Spontaneous Reporting Database
来源期刊:Clinical Drug InvestigationDOI:10.1007/s40261-019-00788-3
The Challenges of Studying Peripheral Vestibular Vertigo
来源期刊:Clinical Drug InvestigationDOI:10.1007/s40261-019-00871-9
Hypertension and Health-Related Quality of Life (HRQoL): Evidence from the US Hispanic Population
来源期刊:Clinical Drug InvestigationDOI:10.1007/s40261-019-00814-4
Effectiveness and Adherence to Treatment with Perindopril/Indapamide/Amlodipine Single-Pill Combination in a Greek Population with Hypertension
来源期刊:Clinical Drug InvestigationDOI:10.1007/s40261-019-00761-0
Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
来源期刊:Clinical Drug InvestigationDOI:10.1007/s40261-019-00863-9
Sunitinib Rechallenge After Other Targeted Therapies in Metastatic Renal Cell Carcinoma Patients: A Single-Center, Retrospective Study
来源期刊:Clinical Drug InvestigationDOI:10.1007/s40261-019-00778-5
Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults
来源期刊:Clinical Drug InvestigationDOI:10.1007/s40261-019-00824-2
Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China
来源期刊:Clinical Drug InvestigationDOI:10.1007/s40261-019-00750-3
Paliperidone Long-Acting Injections in Huntington’s Disease for Motor and Behavioural Disturbances
来源期刊:Clinical Drug InvestigationDOI:10.1007/s40261-019-00759-8
Awareness of, and Compliance with, Domperidone Revised Labeling After a Risk-Minimization Activity in Europe
来源期刊:Clinical Drug InvestigationDOI:10.1007/s40261-019-00831-3
Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study”
来源期刊:Clinical Drug InvestigationDOI:10.1007/s40261-018-0737-y
Early Treatment of Systemic Juvenile Idiopathic Arthritis with Canakinumab and Complete Remission After 2 Years of Treatment Suspension: Case Report of an Adolescent Girl
来源期刊:Clinical Drug InvestigationDOI:10.1007/s40261-019-00766-9
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:
来源期刊:DOI:

质量指标占比

研究类文章占比 OA被引用占比 撤稿占比 出版后修正文章占比
73.13%48%-2.97%

相关指数

影响因子
影响因子
年发文量
自引率
Cite Score

预警情况

查看说明
时间 预警情况
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
*来源:中科院《 国际期刊预警名单》

JCR分区

WOS分区等级:Q2区
版本 按学科 分区
WOS期刊SCI分区
WOS期刊SCI分区
WOS期刊SCI分区是指SCI官方(Web of Science)为每个学科内的期刊按照IF数值排 序,将期刊按照四等分的方法划分的Q1-Q4等级,Q1代表质量最高,即常说的1区期刊。
(2024-2025年最新版)
PHARMACOLOGY & PHARMACY
Q2

中科院分区

查看说明
版本 大类学科 小类学科 Top期刊 综述期刊
2025年3月最新升级版
医学3区
PHARMACOLOGY & PHARMACY 药学
3区
2023年12月升级版
医学3区
PHARMACOLOGY & PHARMACY 药学
3区
2022年12月旧的升级版
医学3区
PHARMACOLOGY & PHARMACY 药学
3区